Trials / Terminated
TerminatedNCT02656615
Abiraterone-Rechallenge Study for CRPC Patients
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Aurelius Omlin · Academic / Other
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
Detailed description
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone. CRPC patients with prior response to abiraterone (confirmed PSA Response) and progression can be re-challenged with abiraterone. Patients may have received treatment with docetaxel, enzalutamide and radium-223.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | abiraterone acetate | Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label). |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2016-01-15
- Last updated
- 2017-03-24
Locations
3 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02656615. Inclusion in this directory is not an endorsement.